00:00:00
Speaker 1: On the beginning during an end of COVID Moderni's CEO Stefan Banzel gave us great, great leadership. We know that is an incredible program the University of Minnesota Biological Engineering. Stefan, I want to go to one of the great people we lost this year, which was a singer songwriter, Jimmy Buffett. He died a skin cancer. What are you going to do about skin cancer? Every listener, every viewer, it's an unspoken fear.
00:00:31
Speaker 2: Well, good morning, and thank you for having me today. And you're right. Today is a huge day of hope for cancer patient in generl and for melanoma patient first. Skin cancer is a scary thing. And what we are doing at Moderonna is wh're using our technology to develop individualized treatment where we make a different chemical drug for different patients. Everybody gets a different drug customized to the DNA of VA cancer cell.
00:01:01
Speaker 3: And the data are striking.
00:01:03
Speaker 2: We compared our drug to the best drug available to the keythedra from mark, a checkpoint inhibitor, and the two year data that we shared a year ago showed forty four percent improvement of free survival of people on this Today. We don't seeing the three year survival is now at forty nine percent. It's already one in two people if you think about it, that are surviving as us the best drug available today to the right. We still have a lot of ideas scientifically manufacturing wise on how we think we can even improve that, and so we are rushing this into a phase three. The phase three is recruiting very quickly, but we're also at the same time because the data is so strong. You know, there's around three thousand people who died of skin can supper year around the world. We're also wanting to talk to regulators to see eaither path for accelerated proboard because the safety profile of toxicity is very similar to that drug kit you drive along, and so you have a very interesting risky world opportunity you have for patients which is one in two chants to make it with our drug right out of three.
00:02:18
Speaker 1: You mentioned Steffan merk Or. I think of Bristol Myers in their commitment to cancer therapy is over decades and decades. Can you do this by going alone or by definition to someone with your huge triumph in COVID, do you need to merge in joint venture in some form with a bigger platform.
00:02:37
Speaker 3: Yes, actually we are partnered with Merk.
00:02:39
Speaker 2: So what is interesting about this study that we are sharing today is we compare two populations. One population gets the Merk drug and the ogre propati get the Merk drug and as an intramuscill also just injected in your arm or product that is customized.
00:02:57
Speaker 3: Individualized for them.
00:02:58
Speaker 2: And that's why you see the big difference of one in two people surviving just use the Merk jraugglon. So when a partner with Merk commercially clinically some clinical studies, modern A team is doing some clinical studies, Milk team is doing well. So not on Monday was starting. We belong to study. As you know, lung is a big killer in cancer. Fortunately we believe that all technology will also have big impact on lung cancer. So very excited and we are going after many more cancers, starting more studies.
00:03:28
Speaker 3: In twenty twenty four.
00:03:30
Speaker 4: Stephan Moderna got a huge boost from the COVID vaccine. We saw that in the share price that it arose tremendously and then it struggled last year, shares lower by almost thirty percent. This year, the shares a lower by fifty six percent. How important is it to you to get the cancer vaccine off the ground to offset the lack of sales in some of the COVID vaccines that we've seen with the latest in particular, Adviser.
00:03:55
Speaker 2: Yeah, So if you think about what happened with the company in twenty nineteen, we had no sas, and then what happened with COVID.
00:04:02
Speaker 3: We add in twenty one eighteen billion dollar our.
00:04:04
Speaker 2: Sales, which is a lot compared to with and a lot of pharmastical companies, and then in twenty twenty one when eighteen billion dollar sales. So in twenty way two and so if you look at it, we are moving into anademic market. As we said in twenty four we antipaid at least four.
00:04:21
Speaker 3: Billion dollar sales. We're gaining market share. We're working on going the market as well.
00:04:26
Speaker 2: But in the US, if you look at it last year, what thirty six percent market share.
00:04:30
Speaker 3: In the last few weeks with fifty two to fifty.
00:04:32
Speaker 2: Three percent market share, we're actually now the leader in the US. And if you look in twenty four we're launching URSV, which is a big opportunity. If you look at what Pfizer and JESK reported in Q three the IC market is around two x what analysts expected. So it's a great face because we believe we're becoming the best product on the market. We have more launches in twenty five through full plus Covid combined and they can sell as early as twenty five, so we're basically going into else growth and the pipe plane is really exciting. We have seven program in phase three, so modern it's sort a one drug company. It's a platform and there's not been platforms before us, so I think a lot of people are still getting the head around what does it look like. But if you look at the all the drugs that are working, we have COVID working and then ls BE working in phase three, and then flu working in phase three, three out of free product in a row with positive phase three. That doesn't happen in pharmaceutical companies because we use old analog technology. We're using an information technology, and so the pace at which we will grow the company I think is going to be quite unprecedented.
00:05:36
Speaker 5: Well, let's talk about your sales team. Your chief commercial officer is leaving as we understand, what are you planning to do differently?
00:05:43
Speaker 2: So actually what we've done is we decided with a board and the team to actually take a layer out because we said the property for twenty four to twenty five is sales, and so now the region's report directly into me. I spent the last two days with a sales team only sweating what we're doing, detail by detail, to grow the market, to gain more market share, and to do a superb launch for OURSV.
00:06:08
Speaker 3: I believe with ours you we're the best product.
00:06:10
Speaker 2: The product of our competitors that are being used today on the market are very cumbersome for pharmacists to prepare. Our product is a profit syringe. We'll be the only product in the market. Look at pharmacy retail. We have even strikes because it's so hard for people in the pharmacy to deal with all the lot of work during the full season. So we're just working on all those things to make sure we drive sales growth and we accelerate ourselves.
00:06:34
Speaker 5: Stephan, I wanted to finish on something quite eloicate. You run quite a polarizing company, celebrated in many ways for the tremendous innovation, but I think there's always going to be a degree of resentment towards companies that benefited from the policy that pushed people to take your products. Do you think that's something you need to repair.
00:06:55
Speaker 2: Look, there was an enemy, which was a virus, and we worked tirelessly, seven days a week to.
00:07:02
Speaker 3: Get the vaccine out.
00:07:04
Speaker 2: It has been shown by several public health analyzes that we saved millions of lives around the world. What policy officially decided to do in different countries around the world was not the company's decision. It was the company's decision of governments. Our enemy was the virus. I think we had a tremendous impact on lives, helped a lot of people, help all of us to go back into the real world in terms of kids going back to school, not worrying about parents, not worrying about friends that have diseases. We are now working on cancer and other things and what this company is about.
00:07:38
Speaker 5: Stephan, appreciate your update and looking forward to more the same in the year to count. Stephan Panser there of maternity
Speaker 1: On the beginning during an end of COVID Moderni's CEO Stefan Banzel gave us great, great leadership. We know that is an incredible program the University of Minnesota Biological Engineering. Stefan, I want to go to one of the great people we lost this year, which was a singer songwriter, Jimmy Buffett. He died a skin cancer. What are you going to do about skin cancer? Every listener, every viewer, it's an unspoken fear.
00:00:31
Speaker 2: Well, good morning, and thank you for having me today. And you're right. Today is a huge day of hope for cancer patient in generl and for melanoma patient first. Skin cancer is a scary thing. And what we are doing at Moderonna is wh're using our technology to develop individualized treatment where we make a different chemical drug for different patients. Everybody gets a different drug customized to the DNA of VA cancer cell.
00:01:01
Speaker 3: And the data are striking.
00:01:03
Speaker 2: We compared our drug to the best drug available to the keythedra from mark, a checkpoint inhibitor, and the two year data that we shared a year ago showed forty four percent improvement of free survival of people on this Today. We don't seeing the three year survival is now at forty nine percent. It's already one in two people if you think about it, that are surviving as us the best drug available today to the right. We still have a lot of ideas scientifically manufacturing wise on how we think we can even improve that, and so we are rushing this into a phase three. The phase three is recruiting very quickly, but we're also at the same time because the data is so strong. You know, there's around three thousand people who died of skin can supper year around the world. We're also wanting to talk to regulators to see eaither path for accelerated proboard because the safety profile of toxicity is very similar to that drug kit you drive along, and so you have a very interesting risky world opportunity you have for patients which is one in two chants to make it with our drug right out of three.
00:02:18
Speaker 1: You mentioned Steffan merk Or. I think of Bristol Myers in their commitment to cancer therapy is over decades and decades. Can you do this by going alone or by definition to someone with your huge triumph in COVID, do you need to merge in joint venture in some form with a bigger platform.
00:02:37
Speaker 3: Yes, actually we are partnered with Merk.
00:02:39
Speaker 2: So what is interesting about this study that we are sharing today is we compare two populations. One population gets the Merk drug and the ogre propati get the Merk drug and as an intramuscill also just injected in your arm or product that is customized.
00:02:57
Speaker 3: Individualized for them.
00:02:58
Speaker 2: And that's why you see the big difference of one in two people surviving just use the Merk jraugglon. So when a partner with Merk commercially clinically some clinical studies, modern A team is doing some clinical studies, Milk team is doing well. So not on Monday was starting. We belong to study. As you know, lung is a big killer in cancer. Fortunately we believe that all technology will also have big impact on lung cancer. So very excited and we are going after many more cancers, starting more studies.
00:03:28
Speaker 3: In twenty twenty four.
00:03:30
Speaker 4: Stephan Moderna got a huge boost from the COVID vaccine. We saw that in the share price that it arose tremendously and then it struggled last year, shares lower by almost thirty percent. This year, the shares a lower by fifty six percent. How important is it to you to get the cancer vaccine off the ground to offset the lack of sales in some of the COVID vaccines that we've seen with the latest in particular, Adviser.
00:03:55
Speaker 2: Yeah, So if you think about what happened with the company in twenty nineteen, we had no sas, and then what happened with COVID.
00:04:02
Speaker 3: We add in twenty one eighteen billion dollar our.
00:04:04
Speaker 2: Sales, which is a lot compared to with and a lot of pharmastical companies, and then in twenty twenty one when eighteen billion dollar sales. So in twenty way two and so if you look at it, we are moving into anademic market. As we said in twenty four we antipaid at least four.
00:04:21
Speaker 3: Billion dollar sales. We're gaining market share. We're working on going the market as well.
00:04:26
Speaker 2: But in the US, if you look at it last year, what thirty six percent market share.
00:04:30
Speaker 3: In the last few weeks with fifty two to fifty.
00:04:32
Speaker 2: Three percent market share, we're actually now the leader in the US. And if you look in twenty four we're launching URSV, which is a big opportunity. If you look at what Pfizer and JESK reported in Q three the IC market is around two x what analysts expected. So it's a great face because we believe we're becoming the best product on the market. We have more launches in twenty five through full plus Covid combined and they can sell as early as twenty five, so we're basically going into else growth and the pipe plane is really exciting. We have seven program in phase three, so modern it's sort a one drug company. It's a platform and there's not been platforms before us, so I think a lot of people are still getting the head around what does it look like. But if you look at the all the drugs that are working, we have COVID working and then ls BE working in phase three, and then flu working in phase three, three out of free product in a row with positive phase three. That doesn't happen in pharmaceutical companies because we use old analog technology. We're using an information technology, and so the pace at which we will grow the company I think is going to be quite unprecedented.
00:05:36
Speaker 5: Well, let's talk about your sales team. Your chief commercial officer is leaving as we understand, what are you planning to do differently?
00:05:43
Speaker 2: So actually what we've done is we decided with a board and the team to actually take a layer out because we said the property for twenty four to twenty five is sales, and so now the region's report directly into me. I spent the last two days with a sales team only sweating what we're doing, detail by detail, to grow the market, to gain more market share, and to do a superb launch for OURSV.
00:06:08
Speaker 3: I believe with ours you we're the best product.
00:06:10
Speaker 2: The product of our competitors that are being used today on the market are very cumbersome for pharmacists to prepare. Our product is a profit syringe. We'll be the only product in the market. Look at pharmacy retail. We have even strikes because it's so hard for people in the pharmacy to deal with all the lot of work during the full season. So we're just working on all those things to make sure we drive sales growth and we accelerate ourselves.
00:06:34
Speaker 5: Stephan, I wanted to finish on something quite eloicate. You run quite a polarizing company, celebrated in many ways for the tremendous innovation, but I think there's always going to be a degree of resentment towards companies that benefited from the policy that pushed people to take your products. Do you think that's something you need to repair.
00:06:55
Speaker 2: Look, there was an enemy, which was a virus, and we worked tirelessly, seven days a week to.
00:07:02
Speaker 3: Get the vaccine out.
00:07:04
Speaker 2: It has been shown by several public health analyzes that we saved millions of lives around the world. What policy officially decided to do in different countries around the world was not the company's decision. It was the company's decision of governments. Our enemy was the virus. I think we had a tremendous impact on lives, helped a lot of people, help all of us to go back into the real world in terms of kids going back to school, not worrying about parents, not worrying about friends that have diseases. We are now working on cancer and other things and what this company is about.
00:07:38
Speaker 5: Stephan, appreciate your update and looking forward to more the same in the year to count. Stephan Panser there of maternity
